Paper830758
Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement.
Welsh RM. J Immunol, 1977. Cited by 57 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. Papers, record 830758. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/830758
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Complement System Proteins | Major topic |
| Lymphocytic choriomeningitis virus | Major topic |
| Newcastle disease virus | Major topic |
| Animals | |
| Cell Line | |
| L Cells | |
| Virus Cultivation |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,766,922 | The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41766922 | PubMed |
| 41,685,933 | Monoclonal IgM antibodies mediate potent complement neutralization by targeting cell-derived epitopes on enveloped viruses. | mBio | 2026 | https://conductscience.org/library/papers/41685933 | PubMed |
| 33,133,089 | In the Crosshairs: RNA Viruses OR Complement? | Front Immunol | 2020 | https://conductscience.org/library/papers/33133089 | PubMed |
| 32,214,620 | Antibody and complement-dependent viral neutralization. | Springer Semin Immunopathol | 1979 | https://conductscience.org/library/papers/32214620 | PubMed |
| 28,670,306 | Complement Evasion Strategies of Viruses: An Overview. | Front Microbiol | 2017 | https://conductscience.org/library/papers/28670306 | PubMed |
| 25,927,683 | Prevalence and characterization of murine leukemia virus contamination in human cell lines. | PLoS One | 2015 | https://conductscience.org/library/papers/25927683 | PubMed |
| 25,409,303 | An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester. | PLoS One | 2014 | https://conductscience.org/library/papers/25409303 | PubMed |
| 23,740,988 | Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primates. | J Virol | 2013 | https://conductscience.org/library/papers/23740988 | PubMed |
| 22,973,037 | Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. | J Virol | 2012 | https://conductscience.org/library/papers/22973037 | PubMed |
| 22,761,385 | Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. | J Virol | 2012 | https://conductscience.org/library/papers/22761385 | PubMed |
| 21,450,814 | Interactions of human complement with virus particles containing the Nipah virus glycoproteins. | J Virol | 2011 | https://conductscience.org/library/papers/21450814 | PubMed |
| 19,457,998 | The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. | J Virol | 2009 | https://conductscience.org/library/papers/19457998 | PubMed |
| 18,440,578 | Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. | Virology | 2008 | https://conductscience.org/library/papers/18440578 | PubMed |
| 10,523,614 | Protective T cell-independent antiviral antibody responses are dependent on complement. | J Exp Med | 1999 | https://conductscience.org/library/papers/10523614 | PubMed |
| 10,467,364 | Human serum-resistant retroviral vector particles from galactosyl (alpha1-3) galactosyl containing nonprimate cell lines. | Gene Ther | 1999 | https://conductscience.org/library/papers/10467364 | PubMed |
| 9,573,228 | Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. | J Virol | 1998 | https://conductscience.org/library/papers/9573228 | PubMed |
| 8,676,446 | Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. | J Virol | 1996 | https://conductscience.org/library/papers/8676446 | PubMed |
| 7,966,590 | Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. | J Virol | 1994 | https://conductscience.org/library/papers/7966590 | PubMed |
| 7,595,205 | A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. | J Exp Med | 1995 | https://conductscience.org/library/papers/7595205 | PubMed |
| 7,045,625 | The complement system: its importance in the host response to viral infection. | Microbiol Rev | 1982 | https://conductscience.org/library/papers/7045625 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/830758
GET https://conductscience.org/api/papers/v1/830758/cited_by?page=2